TITLE
Relapsing-remitting multiple sclerosis therapy of Interferon-β Betaferon or Rebif: peripheral mononuclear blood cells

SUMMARY
Temporal analysis of PBMCs from relapsing-remitting multiple sclerosis (RRMS) patients treated with Interferon-β-1b (Betaferon) or IFNβ-1a (Rebif). Half of the patients developed neutralizing antibodies (NAB) to IFNβ. Results provide insight into molecular basis of IFNβ bioactivity in MS patient

ORGANISM
Homo sapiens

